HNN3.0
Register
Register
Register

Project cooperationUpdated on 27 January 2026

pPAL® DNA Vaccine Platform: From Veterinary Success to Human Translation; New Vaccines for Priority Viruses (HE—Cluster 1, 2026–2027)

Internationalization & Resources Unit Head Manager at Centro de Investigaciones Biológicas Margarita Salas-CSIC

Madrid, Spain

About

pPAL® platform. Our pPAL® platform is a non‑replicating plasmid vector, free of antibiotic‑resistance genes and optimized for GMP‑compliant manufacturing, enabling the rapid design of thermostable, scalable DNA vaccines. The platform has delivered Neoleish® (pPAL LACK), the first DNA vaccine authorized by the EMA in mammals (veterinary use), administered intranasally and demonstrating significant reductions in parasite burden under field conditions; in addition, we have developed COVID‑19 prototypes (pPAL Sfs + pPAL N) that achieved complete protection in the K18‑hACE2 model.

Extensibility to emerging viruses. Our technology is readily transferable to emerging viruses: the evidence generated with pPAL in SARS‑CoV‑2, together with the inherent suitability of DNA vaccines for pandemic response (rapid design, thermal stability, scalable manufacturing), supports extensions to respiratory viruses and arboviruses of interest for the Horizon Europe—Cluster 1 (Health) Work Programme 2026–2027, under the “Tackling diseases and reducing disease burden” Destination and technology‑oriented Destinations.

Topic

  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential

Type

  • Partner seeks Consortium/Coordinator

Organisation

Similar opportunities